Bausch Health Companies (TSE:BHC) Upgraded to Hold at Evercore ISI

Posted by Samantha Reynolds on Oct 17th, 2024

Evercore ISI upgraded shares of Bausch Health Companies (TSE:BHC – Free Report) to a hold rating in a report released on Tuesday, Zacks.com reports.

Separately, Raymond James upgraded shares of Bausch Health Companies to a “hold” rating in a research report on Wednesday, July 10th.

View Our Latest Research Report on BHC

Bausch Health Companies Stock Performance

TSE BHC opened at C$11.66 on Tuesday. The company has a debt-to-equity ratio of 7,583.76, a current ratio of 1.19 and a quick ratio of 0.58. The stock’s 50 day simple moving average is C$9.17 and its 200-day simple moving average is C$10.00. The company has a market cap of C$4.28 billion, a PE ratio of -6.66, a price-to-earnings-growth ratio of 0.21 and a beta of 0.77. Bausch Health Companies has a 1-year low of C$5.45 and a 1-year high of C$15.43.

Bausch Health Companies (TSE:BHC – Get Free Report) last announced its quarterly earnings data on Thursday, August 1st. The company reported C$1.22 earnings per share for the quarter, meeting analysts’ consensus estimates of C$1.22. Bausch Health Companies had a negative return on equity of 2,304.54% and a negative net margin of 5.12%. The company had revenue of C$3.29 billion for the quarter, compared to analyst estimates of C$3.20 billion. As a group, equities research analysts anticipate that Bausch Health Companies will post 5.5472637 EPS for the current fiscal year.

Insider Buying and Selling

In other Bausch Health Companies news, Senior Officer Seana Lynne Carson sold 13,370 shares of the company’s stock in a transaction on Friday, September 6th. The stock was sold at an average price of C$8.38, for a total value of C$112,087.40. 11.28% of the stock is currently owned by company insiders.

Bausch Health Companies Company Profile

(Get Free Report)

Bausch Health Companies Inc operates as a diversified specialty pharmaceutical and medical device company in the United States and internationally. It develops, manufactures, and markets a range of products primarily in gastroenterology, hepatology, neurology, dermatology, international pharmaceuticals, over-the-counter (OTC) products, aesthetic medical devices, and eye health.